Navigation Links
Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society

RESEARCH TRIANGLE PARK, N.C., July 9, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the 24th International Congress of the Transplantation Society being held July 15-19th, 2012 at the International Congress Centre Berlin in Berlin, Germany.  The poster presentation, entitled "CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK Virus (BKV) Associated Bladder and Kidney End-Organ Damage," is part of the Late Breaking Abstracts session on Monday, July 16th from 12:15-13:30 pm in the Stockholm room.

Herve Mommeja-Marin, MD, Vice President of Clinical Research at Chimerix, will present the data from Study 201, Chimerix's Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cells transplant (HSCT) recipients.  Phase 2 results presented elsewhere have shown that CMX001, at various doses, was active and well-tolerated in the prevention of CMV infection or disease.  This new retrospective analysis focuses on BK virus and shows that CMX001 may prevent end-organ damage in subjects who had BKV infection in the urine upon initiation of therapy.

About Chimerix Chimerix is developing novel antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology platform has given rise to Chimerix's two clinical stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

Chimerix's lead candidate, CMX001, is a novel, broad spectrum nucleoside analog that is anabolized intracellularly and inhibits double-stranded DNA (dsDNA) viruses including CMV, adenovirus (AdV), BKV, and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of AdV infection in HSCT recipients.  Antiviral activity from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity that are associated with currently available therapies, indicate that CMX001 has the potential to improve outcomes for stem cell and solid organ transplant recipients. 

Chimerix has completed an End of Phase 2 meeting with the FDA for CMX001 and is preparing to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients.  To date, more than 750 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Under a contract from the Biomedical Advanced Research and Development Authority (BARDA), CMX001 is also being developed as a medical countermeasure to protect against a bioterror threat in the event of a smallpox release. 

Chimerix is also developing CMX157, a novel nucleoside analog that delivers high intracellular levels of the active antiviral agent, tenofovir diphosphate.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile.  High intracellular concentrations of the active antiviral and a long-lasting intracellular half-life may allow for infrequent dosing and therefore increased dosing convenience.  In addition, CMX157 exhibited highly potent in vitro activity against HIV, including HIV resistant to current therapies, and against HBV. 

Led by an experienced antiviral drug development team, Chimerix is also leveraging its lipid technology and novel chemical library to pursue new treatments for other areas of high unmet medical need.  For additional information on Chimerix, please visit  




SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
4. Merz, Inc. Announces Promotion of Katrina Church to Vice President, Chief Compliance Officer
5. Akorn, Inc. Announces Second Quarter 2012 Earnings Release And Conference Call Information
6. ShangPharma Announces Receipt of "Going Private" Proposal at $8.50 to $9.50 Per ADS
7. Aoxing Pharmaceutical Company Announces Management Change
8. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
9. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
10. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
11. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
Post Your Comments:
(Date:11/24/2015)... -- Teledyne DALSA , a Teledyne Technologies company and ... its CMOS X-Ray detector for mammography at the ... 3, at McCormick Place in Chicago . ... imaging will be on display in the South Hall, Booth ... X-Ray detectors is the industry benchmark for high speed imaging ...
(Date:11/24/2015)... 24, 2015 The uptake of recently approved and ... key driver of market growth to 2021, says GBI ... pipeline premium products for Type 1 Diabetes Mellitus (T1DM), will be a ... Research . --> The uptake of recently approved ... a key driver of market growth to 2021, says ...
(Date:11/24/2015)... NEWTOWN, Pa. , Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen ... mobile and stationary computer technology as part of their patient monitoring or electronic documentation system. ... ... ... ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... The ... comes to several aspects of orthopedic care. They have received recognition for excellence ... general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based ...
(Date:11/24/2015)... Salt Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... according to Forbes Magazine. For a business, it is critical that the first impression ... of a business, they are not likely to buy anything or want to return. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy ... Brillouin is the developer of renewable energy technologies capable of producing commercially useful ... announced today that its WET™ and HHT™ Boiler System reactor core modules were ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit ... welcome Winter-Dent & Company as its newest Partner Firm. Based in Jefferson City, ... client's most trusted advisor regardless of whether that client is a business, a ...
(Date:11/24/2015)... ALEXANDRIA, VA (PRWEB) , ... November 24, 2015 ... ... encourages people across the United States to support their local poison centers through ... been designated as #GivingTuesday: calls it “a day that inspires people to ...
Breaking Medicine News(10 mins):